Search Results

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.

Actinium Pharmaceuticals, Inc. announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society being held April 14 – 17, 2024, in Glasgow, Scotland.

Sierra Oncology, Inc. today reported its financial and operating results for the first quarter ended March 31, 2022.

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022.

Sierra Oncology, Inc. today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021.